These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22245662)

  • 1. Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.
    Lopez S; Jouve L; Turle-Lorenzo N; Kerkerian-Legoff L; Salin P; Amalric M
    Neurobiol Dis; 2012 Apr; 46(1):69-77. PubMed ID: 22245662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
    Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
    Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
    Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
    Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
    Lopez S; Turle-Lorenzo N; Acher F; De Leonibus E; Mele A; Amalric M
    J Neurosci; 2007 Jun; 27(25):6701-11. PubMed ID: 17581957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
    Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
    Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrasubthalamic nucleus metabotropic glutamate receptor activation: a behavioral, Fos immunohistochemical and [14C]2-deoxyglucose autoradiographic study.
    Kearney JA; Albin RL
    Neuroscience; 2000; 95(2):409-16. PubMed ID: 10658620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
    Johnson KA; Jones CK; Tantawy MN; Bubser M; Marvanova M; Ansari MS; Baldwin RM; Conn PJ; Niswender CM
    Neuropharmacology; 2013 Mar; 66():187-95. PubMed ID: 22546615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid.
    Chapman AG; Talebi A; Yip PK; Meldrum BS
    Eur J Pharmacol; 2001 Jul; 424(2):107-13. PubMed ID: 11476756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats.
    Tatarczyńska E; Pałucha A; Szewczyk B; Chojnacka-Wójcik E; Wierońska J; Pilc A
    Pol J Pharmacol; 2002; 54(6):707-10. PubMed ID: 12866729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.
    MacInnes N; Messenger MJ; Duty S
    Br J Pharmacol; 2004 Jan; 141(1):15-22. PubMed ID: 14597605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
    Broadstock M; Austin PJ; Betts MJ; Duty S
    Br J Pharmacol; 2012 Feb; 165(4b):1034-45. PubMed ID: 21627638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
    Konieczny J; Lenda T
    Pharmacol Rep; 2013; 65(5):1194-203. PubMed ID: 24399715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.
    Pałucha-Poniewiera A; Novák K; Pilc A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1454-7. PubMed ID: 19660510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies.
    Domin H; Przykaza Ł; Jantas D; Kozniewska E; Boguszewski PM; Śmiałowska M
    Neuropharmacology; 2016 Mar; 102():276-94. PubMed ID: 26647070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
    Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
    Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
    Kaneda K; Tachibana Y; Imanishi M; Kita H; Shigemoto R; Nambu A; Takada M
    Eur J Neurosci; 2005 Dec; 22(12):3241-54. PubMed ID: 16367790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.
    Breysse N; Amalric M; Salin P
    J Neurosci; 2003 Sep; 23(23):8302-9. PubMed ID: 12967992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
    Oueslati A; Breysse N; Amalric M; Kerkerian-Le Goff L; Salin P
    Eur J Neurosci; 2005 Dec; 22(11):2765-74. PubMed ID: 16324110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.
    Bradley SR; Marino MJ; Wittmann M; Rouse ST; Awad H; Levey AI; Conn PJ
    J Neurosci; 2000 May; 20(9):3085-94. PubMed ID: 10777772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
    Greco B; Lopez S; van der Putten H; Flor PJ; Amalric M
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1064-71. PubMed ID: 19940105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.